News | November 03, 2021
Covaxin shelf-life extended to 12 months from the date of manufacture
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
Bharat Biotech has been submitting data to the WHO on a rolling basis and submitted additional information at WHO’s request on September 27th 2021
The trial will be conducted across 10 sites in India
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
